51.8 USD
+0.35 (+0.68%)
51.6 USD
-0.2 (-0.39%)
We assign a fundamental rating of 5 out of 10 to SUPN. SUPN was compared to 190 industry peers in the Pharmaceuticals industry. SUPN has only an average score on both its financial health and profitability. SUPN has a correct valuation and a medium growth rate.
1. Profitability
1.1 Basic Checks
- SUPN had positive earnings in the past year.
- In the past year SUPN had a positive cash flow from operations.
- In the past 5 years SUPN has always been profitable.
- SUPN had a positive operating cash flow in each of the past 5 years.
1.2 Ratios
- With a decent Return On Assets value of -1.35%, SUPN is doing good in the industry, outperforming 75.26% of the companies in the same industry.
- SUPN's Return On Equity of -1.82% is fine compared to the rest of the industry. SUPN outperforms 77.37% of its industry peers.
- With a decent Return On Invested Capital value of 2.34%, SUPN is doing good in the industry, outperforming 79.47% of the companies in the same industry.
- SUPN had an Average Return On Invested Capital over the past 3 years of 2.70%. This is significantly below the industry average of 12.84%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -1.35% | ||
| ROE | -1.82% | ||
| ROIC | 2.34% |
ROA(3y)3.02%
ROA(5y)4.13%
ROE(3y)4.71%
ROE(5y)7.54%
ROIC(3y)2.7%
ROIC(5y)4.37%
1.3 Margins
- In the last couple of years the Profit Margin of SUPN has declined.
- SUPN has a Operating Margin of 6.08%. This is in the better half of the industry: SUPN outperforms 79.47% of its industry peers.
- SUPN's Operating Margin has declined in the last couple of years.
- Looking at the Gross Margin, with a value of 89.91%, SUPN belongs to the top of the industry, outperforming 92.11% of the companies in the same industry.
- SUPN's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 6.08% | ||
| PM (TTM) | N/A | ||
| GM | 89.91% |
OM growth 3Y-9.85%
OM growth 5Y-18.4%
PM growth 3Y6.61%
PM growth 5Y-17.27%
GM growth 3Y0.96%
GM growth 5Y-1.32%
2. Health
2.1 Basic Checks
- SUPN has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
- Compared to 1 year ago, SUPN has more shares outstanding
- Compared to 5 years ago, SUPN has more shares outstanding
- SUPN has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
- SUPN has an Altman-Z score of 6.13. This indicates that SUPN is financially healthy and has little risk of bankruptcy at the moment.
- SUPN's Altman-Z score of 6.13 is fine compared to the rest of the industry. SUPN outperforms 76.32% of its industry peers.
- There is no outstanding debt for SUPN. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Altman-Z | 6.13 |
ROIC/WACC0.25
WACC9.39%
2.3 Liquidity
- A Current Ratio of 1.80 indicates that SUPN should not have too much problems paying its short term obligations.
- SUPN has a worse Current ratio (1.80) than 66.32% of its industry peers.
- SUPN has a Quick Ratio of 1.56. This is a normal value and indicates that SUPN is financially healthy and should not expect problems in meeting its short term obligations.
- SUPN has a Quick ratio of 1.56. This is in the lower half of the industry: SUPN underperforms 61.58% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.8 | ||
| Quick Ratio | 1.56 |
3. Growth
3.1 Past
- The Earnings Per Share has been growing slightly by 0.32% over the past year.
- Measured over the past 5 years, SUPN shows a small growth in Earnings Per Share. The EPS has been growing by 6.93% on average per year.
- The Revenue has been growing slightly by 4.54% in the past year.
- Measured over the past years, SUPN shows a quite strong growth in Revenue. The Revenue has been growing by 11.00% on average per year.
EPS 1Y (TTM)0.32%
EPS 3Y44.39%
EPS 5Y6.93%
EPS Q2Q%-13.68%
Revenue 1Y (TTM)4.54%
Revenue growth 3Y4.51%
Revenue growth 5Y11%
Sales Q2Q%9.34%
3.2 Future
- SUPN is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 19.52% yearly.
- The Revenue is expected to grow by 14.93% on average over the next years. This is quite good.
EPS Next Y-3.99%
EPS Next 2Y21.18%
EPS Next 3Y17.74%
EPS Next 5Y19.52%
Revenue Next Year9.32%
Revenue Next 2Y16.13%
Revenue Next 3Y15.75%
Revenue Next 5Y14.93%
3.3 Evolution
- The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
- The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
- The Price/Earnings ratio is 16.71, which indicates a correct valuation of SUPN.
- Compared to the rest of the industry, the Price/Earnings ratio of SUPN indicates a rather cheap valuation: SUPN is cheaper than 84.74% of the companies listed in the same industry.
- When comparing the Price/Earnings ratio of SUPN to the average of the S&P500 Index (27.33), we can say SUPN is valued slightly cheaper.
- Based on the Price/Forward Earnings ratio of 11.96, the valuation of SUPN can be described as reasonable.
- Compared to the rest of the industry, the Price/Forward Earnings ratio of SUPN indicates a rather cheap valuation: SUPN is cheaper than 85.79% of the companies listed in the same industry.
- Compared to an average S&P500 Price/Forward Earnings ratio of 24.12, SUPN is valued rather cheaply.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 16.71 | ||
| Fwd PE | 11.96 |
4.2 Price Multiples
- Based on the Enterprise Value to EBITDA ratio, SUPN is valued a bit cheaper than the industry average as 80.00% of the companies are valued more expensively.
- Compared to the rest of the industry, the Price/Free Cash Flow ratio of SUPN indicates a somewhat cheap valuation: SUPN is cheaper than 78.95% of the companies listed in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 41.98 | ||
| EV/EBITDA | 20.17 |
4.3 Compensation for Growth
- SUPN's earnings are expected to grow with 17.74% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)2.41
EPS Next 2Y21.18%
EPS Next 3Y17.74%
5. Dividend
5.1 Amount
- No dividends for SUPN!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
51.8
+0.35 (+0.68%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)11-04 2025-11-04/amc
Earnings (Next)02-23 2026-02-23/amc
Inst Owners104.2%
Inst Owner Change0%
Ins Owners4.26%
Ins Owner Change2.8%
Market Cap2.97B
Revenue(TTM)681.54M
Net Income(TTM)-19.12M
Analysts83.33
Price Target62.56 (20.77%)
Short Float %8.77%
Short Ratio5.61
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)77.78%
Min EPS beat(2)67.83%
Max EPS beat(2)87.73%
EPS beat(4)4
Avg EPS beat(4)62.07%
Min EPS beat(4)15.55%
Max EPS beat(4)87.73%
EPS beat(8)7
Avg EPS beat(8)65.74%
EPS beat(12)9
Avg EPS beat(12)51.6%
EPS beat(16)10
Avg EPS beat(16)29.18%
Revenue beat(2)2
Avg Revenue beat(2)5.28%
Min Revenue beat(2)5.28%
Max Revenue beat(2)5.29%
Revenue beat(4)3
Avg Revenue beat(4)4.96%
Min Revenue beat(4)-0.71%
Max Revenue beat(4)9.98%
Revenue beat(8)6
Avg Revenue beat(8)5.09%
Revenue beat(12)8
Avg Revenue beat(12)3.15%
Revenue beat(16)11
Avg Revenue beat(16)2.6%
PT rev (1m)1.38%
PT rev (3m)40.03%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-56.74%
EPS NY rev (1m)0%
EPS NY rev (3m)24.89%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-1.53%
Revenue NY rev (1m)0%
Revenue NY rev (3m)1.51%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 16.71 | ||
| Fwd PE | 11.96 | ||
| P/S | 4.36 | ||
| P/FCF | 41.98 | ||
| P/OCF | 41.32 | ||
| P/B | 2.83 | ||
| P/tB | 9.67 | ||
| EV/EBITDA | 20.17 |
EPS(TTM)3.1
EY5.98%
EPS(NY)4.33
Fwd EY8.36%
FCF(TTM)1.23
FCFY2.38%
OCF(TTM)1.25
OCFY2.42%
SpS11.89
BVpS18.31
TBVpS5.36
PEG (NY)N/A
PEG (5Y)2.41
Graham Number35.73
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -1.35% | ||
| ROE | -1.82% | ||
| ROCE | 3.81% | ||
| ROIC | 2.34% | ||
| ROICexc | 3.16% | ||
| ROICexgc | 38.99% | ||
| OM | 6.08% | ||
| PM (TTM) | N/A | ||
| GM | 89.91% | ||
| FCFM | 10.38% |
ROA(3y)3.02%
ROA(5y)4.13%
ROE(3y)4.71%
ROE(5y)7.54%
ROIC(3y)2.7%
ROIC(5y)4.37%
ROICexc(3y)4.39%
ROICexc(5y)6.6%
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)4.82%
ROCE(5y)7.36%
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3Y11.61%
ROICexc growth 5Y-8.56%
OM growth 3Y-9.85%
OM growth 5Y-18.4%
PM growth 3Y6.61%
PM growth 5Y-17.27%
GM growth 3Y0.96%
GM growth 5Y-1.32%
F-Score4
Asset Turnover0.48
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Debt/EBITDA | 0 | ||
| Cap/Depr | 1.32% | ||
| Cap/Sales | 0.16% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 56.66% | ||
| Profit Quality | N/A | ||
| Current Ratio | 1.8 | ||
| Quick Ratio | 1.56 | ||
| Altman-Z | 6.13 |
F-Score4
WACC9.39%
ROIC/WACC0.25
Cap/Depr(3y)0.67%
Cap/Depr(5y)5.39%
Cap/Sales(3y)0.09%
Cap/Sales(5y)0.25%
Profit Quality(3y)2940.94%
Profit Quality(5y)1832.68%
High Growth Momentum
Growth
EPS 1Y (TTM)0.32%
EPS 3Y44.39%
EPS 5Y6.93%
EPS Q2Q%-13.68%
EPS Next Y-3.99%
EPS Next 2Y21.18%
EPS Next 3Y17.74%
EPS Next 5Y19.52%
Revenue 1Y (TTM)4.54%
Revenue growth 3Y4.51%
Revenue growth 5Y11%
Sales Q2Q%9.34%
Revenue Next Year9.32%
Revenue Next 2Y16.13%
Revenue Next 3Y15.75%
Revenue Next 5Y14.93%
EBIT growth 1Y-47.81%
EBIT growth 3Y-5.79%
EBIT growth 5Y-9.43%
EBIT Next Year10.08%
EBIT Next 3Y40.06%
EBIT Next 5Y32.85%
FCF growth 1Y-23.92%
FCF growth 3Y11.03%
FCF growth 5Y4.05%
OCF growth 1Y-23.21%
OCF growth 3Y10.6%
OCF growth 5Y3.74%
SUPERNUS PHARMACEUTICALS INC / SUPN FAQ
Can you provide the ChartMill fundamental rating for SUPERNUS PHARMACEUTICALS INC?
ChartMill assigns a fundamental rating of 5 / 10 to SUPN.
What is the valuation status for SUPN stock?
ChartMill assigns a valuation rating of 6 / 10 to SUPERNUS PHARMACEUTICALS INC (SUPN). This can be considered as Fairly Valued.
What is the profitability of SUPN stock?
SUPERNUS PHARMACEUTICALS INC (SUPN) has a profitability rating of 5 / 10.
Can you provide the expected EPS growth for SUPN stock?
The Earnings per Share (EPS) of SUPERNUS PHARMACEUTICALS INC (SUPN) is expected to decline by -3.99% in the next year.